🚀 VC round data is live in beta, check it out!
Dishman Carbogen Amics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Dishman Carbogen Amics and similar public comparables like Shattuck Labs, Opus Genetics, Flerie, C4 Therapeutics and more.
Dishman Carbogen Amics Overview
About Dishman Carbogen Amics
Dishman Carbogen Amics Ltd is a biotechnology company that provides contract research and manufacturing services for pharmaceutical companies. It manufactures bulk drugs, specialty chemicals, and outsourced goods. Additionally, the company produces vitamins, such as vitamin D2 and vitamin D3, reagents, antiseptics and disinfectants, transfer catalysts, personal-care ingredients, pharma intermediates, and ammonium and phosphonium high-purity solid Quats. The business generates the vast majority of its revenue in India.
Founded
2007
HQ
Employees
1.1K
Website
Financials (FY)
EV
$507M
Dishman Carbogen Amics Financials
Dishman Carbogen Amics reported last fiscal year revenue of $285M and EBITDA of $50M.
In the same fiscal year, Dishman Carbogen Amics generated $229M in gross profit, $50M in EBITDA, and $350K in net income.
Revenue (LTM)
Dishman Carbogen Amics P&L
In the most recent fiscal year, Dishman Carbogen Amics reported revenue of $285M and EBITDA of $50M.
Dishman Carbogen Amics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $285M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $229M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 80% | XXX | XXX | XXX |
| EBITDA | — | XXX | $50M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 18% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 6% | XXX | XXX | XXX |
| Net Profit | — | XXX | $350K | XXX | XXX | XXX |
| Net Margin | — | XXX | 0% | XXX | XXX | XXX |
| Net Debt | — | — | $194M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Dishman Carbogen Amics Stock Performance
Dishman Carbogen Amics has current market cap of $299M, and enterprise value of $507M.
Market Cap Evolution
Dishman Carbogen Amics' stock price is $1.91.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $507M | $299M | 0.0% | XXX | XXX | XXX | $0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDishman Carbogen Amics Valuation Multiples
Dishman Carbogen Amics trades at 1.8x EV/Revenue multiple, and 10.1x EV/EBITDA.
EV / Revenue (LTM)
Dishman Carbogen Amics Financial Valuation Multiples
As of March 16, 2026, Dishman Carbogen Amics has market cap of $299M and EV of $507M.
Equity research analysts estimate Dishman Carbogen Amics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Dishman Carbogen Amics has a P/E ratio of 854.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $299M | XXX | $299M | XXX | XXX | XXX |
| EV (current) | $507M | XXX | $507M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 1.8x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 10.1x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 32.2x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 2.2x | XXX | XXX | XXX |
| P/E | — | XXX | 854.8x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 29.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Dishman Carbogen Amics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Dishman Carbogen Amics Margins & Growth Rates
Dishman Carbogen Amics' revenue in the last fiscal year grew by 1%.
Dishman Carbogen Amics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 1% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 18% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 10% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 75% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Dishman Carbogen Amics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Contract Research & Manufacturing comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Shattuck Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Opus Genetics | XXX | XXX | XXX | XXX | XXX | XXX |
| Flerie | XXX | XXX | XXX | XXX | XXX | XXX |
| C4 Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Rezolute | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Dishman Carbogen Amics M&A Activity
Dishman Carbogen Amics acquired XXX companies to date.
Last acquisition by Dishman Carbogen Amics was on XXXXXXXX, XXXXX. Dishman Carbogen Amics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Dishman Carbogen Amics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialDishman Carbogen Amics Investment Activity
Dishman Carbogen Amics invested in XXX companies to date.
Dishman Carbogen Amics made its latest investment on XXXXXXXX, XXXXX. Dishman Carbogen Amics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Dishman Carbogen Amics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Dishman Carbogen Amics
| When was Dishman Carbogen Amics founded? | Dishman Carbogen Amics was founded in 2007. |
| Where is Dishman Carbogen Amics headquartered? | Dishman Carbogen Amics is headquartered in India. |
| How many employees does Dishman Carbogen Amics have? | As of today, Dishman Carbogen Amics has over 1K employees. |
| Is Dishman Carbogen Amics publicly listed? | Yes, Dishman Carbogen Amics is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Dishman Carbogen Amics? | Dishman Carbogen Amics trades under DCAL ticker. |
| When did Dishman Carbogen Amics go public? | Dishman Carbogen Amics went public in 2004. |
| Who are competitors of Dishman Carbogen Amics? | Dishman Carbogen Amics main competitors are Shattuck Labs, Opus Genetics, Flerie, C4 Therapeutics. |
| What is the current market cap of Dishman Carbogen Amics? | Dishman Carbogen Amics' current market cap is $299M. |
| What is the current revenue of Dishman Carbogen Amics? | Dishman Carbogen Amics' last fiscal year revenue is $285M. |
| What is the current EV/Revenue multiple of Dishman Carbogen Amics? | Current revenue multiple of Dishman Carbogen Amics is 1.8x. |
| Is Dishman Carbogen Amics profitable? | No, Dishman Carbogen Amics is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.